With the growing strategy of using CAR T cells to reset the pathogenic humoral immune responses in autoimmune disease, a clinical trial of CD19-targeting sCAR T cells has been registered and is currently recruiting (NCT06913608). Here, CD19 is linked to autoimmune disease.